Hanmi Pharm Co (128940.KS) Stock Price
Hanmi Pharm Co Price
Revenue has compounded at 6.1% per year over the past 18 years to 1.55 T KRW. Earnings per share have grown at 6.9% per year over the last 18 years. Hanmi Pharm Co's net margin stands at 11.0%, up from 5.6% several years earlier. Hanmi Pharm Co currently offers a dividend yield of about 0.26%. The payout ratio is around 12% of earnings. Analysts set a median price target of 540,600.00 KRW, implying 12.9% above the current price. Of 23 analysts, 22 rate the stock a buy — an overall Buy consensus.
Hanmi Pharm Co stock price
Hanmi Pharm Co business model & stock analysis
Frequently asked questions about Hanmi Pharm Co
The business model of Hanmi Pharm Co Ltd is focused on pharmaceutical research and development, manufacturing, and sales. Hanmi Pharm specializes in developing innovative drugs for various therapeutic areas including diabetes, cardiovascular diseases, cancer, and rare diseases. The company also actively engages in strategic collaborations and licensing agreements to expand its product pipeline and market reach globally. Hanmi Pharm strives to enhance patients' quality of life through its advanced healthcare solutions and aims to become a leading global biopharmaceutical company.
Hanmi Pharm Co Ltd is primarily active in the pharmaceutical industry.
The main competitors of Hanmi Pharm Co Ltd in the market include multinational pharmaceutical companies such as Pfizer, Novartis, and AstraZeneca. These companies have a global presence and offer a wide range of pharmaceutical products and solutions, making them strong competitors in the industry. Despite facing competition from these established players, Hanmi Pharm Co Ltd has carved a niche for itself through its focus on innovative drug development, strategic partnerships, and strong distribution networks. This enables Hanmi Pharm Co Ltd to maintain its competitiveness and continue to thrive in the pharmaceutical market.
Hanmi Pharm Co Ltd, established in 1973, is a leading pharmaceutical company based in South Korea. With a strong focus on research and development, Hanmi Pharm has grown to become a global player in the healthcare industry. The company specializes in the development, manufacturing, and commercialization of innovative and high-quality pharmaceutical products. Hanmi Pharm's dedication to innovation has led to significant breakthroughs in various therapeutic areas, including oncology, diabetes, and rare diseases. The company's commitment to excellence and its strategic partnerships have enabled it to expand its presence and impact in markets worldwide. Hanmi Pharm Co Ltd continues to strive towards improving global healthcare by delivering innovative solutions and improving patients' lives.
Hanmi Pharm Co Ltd has achieved several significant milestones throughout its history. One notable accomplishment for the company was the successful development and commercialization of their anti-diabetic drug, Empagliflozin. This drug has become a breakthrough in the treatment of type 2 diabetes and has garnered recognition worldwide. Another milestone for Hanmi Pharm Co Ltd was the establishment of strategic partnerships with renowned global pharmaceutical companies, such as Sanofi and Boehringer Ingelheim, further enhancing their presence in the international market. These achievements highlight Hanmi Pharm Co Ltd's commitment to research and innovation, positioning them as a notable player in the pharmaceutical industry.
Hanmi Pharm Co Ltd is primarily present in South Korea.
Hanmi Pharm Co Ltd is a renowned pharmaceutical company that values innovation, integrity, and excellence. With a strong corporate philosophy focused on improving global health, Hanmi Pharm Co Ltd strives to develop cutting-edge solutions and provide accessible healthcare to people worldwide. Through continuous research and development, the company emphasizes improving patient outcomes and enhancing the quality of life. Hanmi Pharm Co Ltd's commitment to these values has enabled it to establish a strong presence in the industry and gain recognition for its high-quality products and services.
Analysts currently set an average price target of 507,085.71 KRW for the Hanmi Pharm Co stock (median: 540,600.00 KRW), implying +5.9 % versus the latest price. The consensus is based on 23 analyst ratings.
23 analysts currently rate the Hanmi Pharm Co stock: 22 recommend buying, 1 holding and 0 selling. For 2026, analysts expect Hanmi Pharm Co to generate revenue of 1.77 T KRW and earnings per share of 23,739.62 KRW.
Converted at the current exchange rate, the Hanmi Pharm Co share trades at 318.52 EUR (479,000.00 KRW).
The Hanmi Pharm Co share (128940.KS) is listed on 1 stock exchanges, including: KOSPI (Seoul) (128940.KS).
Hanmi Pharm Co Ltd is a leading biopharmaceutical company based in South Korea. The company operates in various sectors including the development, production, and marketing of pharmaceuticals and pharmaceutical products, diagnostic devices, and medical equipment. It specializes in the production of biosimilars, diagnostic devices, and medical equipment. It is focused on expanding its business model through partnerships and international market expansion.
The expected revenue of Hanmi Pharm Co is 1.77 T KRW. This figure is based on current financial data and reflects the company's business performance.
The expected profit of Hanmi Pharm Co is 274.01 B KRW. The net profit reflects the company's profitability after deducting all expenses.
The price-to-earnings ratio (P/E) of Hanmi Pharm Co is currently 20.18. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the Hanmi Pharm Co stock.
The price-to-sales ratio (P/S) of Hanmi Pharm Co is currently 3.12. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the Hanmi Pharm Co stock.
The Eulerpool Quality Score for Hanmi Pharm Co is 4/10.
The ISIN of Hanmi Pharm Co is KR7128940004. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.
The ticker of Hanmi Pharm Co is 128940.KS. The ticker symbol is used to trade Hanmi Pharm Co shares on the stock exchange.
Hanmi Pharm Co stock
Hanmi Pharm Co Peer Group
Hanmi Pharm Co Ticker
Hanmi Pharm Co FIGI
All fundamentals and in-depth analysis of Hanmi Pharm Co
Our stock analysis for Hanmi Pharm Co stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Hanmi Pharm Co. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.